Drugs / AM1476
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04691115 | Dec 2020 → Dec 2021 | — | AnaMar AB | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-23 | AnaMar AB | Results Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis anamar.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-05-23 | AnaMar AB | Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis anamar.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AM1476 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04691115 ↗ |
| Route | Oral | “single and multiple ascending oral doses of AM1476” NCT04691115 ↗ |